quinazolines has been researched along with Hyperglycemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bouabdallah, K; Childs, BH; Demeter, J; Dimou, M; Dreyling, M; Follows, G; Garcia-Vargas, J; Hiemeyer, F; Kim, WS; Kosinova, M; Lenz, G; Leppä, S; Miriyala, A; Mollica, L; Morschhauser, F; Munoz, J; Nagler, A; Özcan, M; Rodrigues, L; Santoro, A; Stevens, DA; Trevarthen, D; Zinzani, PL | 1 |
| Cheson, BD; Narkhede, M | 1 |
| Grunberger, G | 1 |
| Barnett, AH; Lewin, AJ; McGill, JB; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Dugi, K; Hehnke, U; Heise, T; Larbig, M; Patel, S; Seck, T; Woerle, HJ | 1 |
| Bailes, Z; Caballero, AE; Del Prato, S; Gallwitz, B; Lewis-D'Agostino, D; Patel, S; Ross, SA; Thiemann, S; von Eynatten, M; Woerle, HJ | 1 |
| Akhtar, S; Al-Khaldi, AT; Attur, S; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Sarkhou, F; Yousif, MH | 1 |
| Bian, K; Chen, HH; He, YQ; Murad, F; Nie, XQ; Pan, HJ; Song, WX; Yang, JW; Zhang, JY; Zhang, YJ | 1 |
| Gerich, J | 1 |
| Akhtar, S; Al-Farsi, O; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Yousif, MH | 1 |
| Haak, T | 1 |
| Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P | 1 |
| Bursell, SE; Clermont, AC; Ishii, H; King, GL; Mori, F; Takagi, C; Takagi, H | 1 |
| Fujii, T; Inoue, S; Nagai, K; Nakagawa, H | 1 |
5 review(s) available for quinazolines and Hyperglycemia
| Article | Year |
|---|---|
Copanlisib in the treatment of non-Hodgkin lymphoma.
Topics: Biomarkers; Clinical Trials as Topic; Disease Management; Disease Susceptibility; Humans; Hyperglycemia; Hypertension; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Pyrimidines; Quinazolines; Signal Transduction; Treatment Outcome | 2020 |
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2013 |
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Linagliptin; Postprandial Period; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Practice Guidelines as Topic; Purines; Quinazolines | 2012 |
2 trial(s) available for quinazolines and Hyperglycemia
| Article | Year |
|---|---|
Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonylurea Compounds | 2014 |
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; International Cooperation; Linagliptin; Metformin; Purines; Quinazolines; Treatment Outcome | 2015 |
7 other study(ies) available for quinazolines and Hyperglycemia
| Article | Year |
|---|---|
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypertension; Lymphoma, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Pyrimidines; Quinazolines; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2020 |
The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; ErbB Receptors; Hyperglycemia; Lapatinib; Male; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2015 |
Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways.
Topics: Animals; Dietary Fats; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Indole Alkaloids; Liver; Male; Muscle Cells; Muscle, Skeletal; Pancreas; Quinazolines; Rats, Sprague-Dawley; Signal Transduction; Streptozocin | 2016 |
Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway.
Topics: Angiotensin I; Angiotensin II; Animals; Body Weight; Diabetes Mellitus; ErbB Receptors; Glucose; Hyperglycemia; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Quinazolines; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; src-Family Kinases; Transcriptional Activation; Tyrphostins | 2012 |
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
Topics: Animals; Blood Flow Velocity; Diabetes Mellitus, Experimental; Diacylglycerol Kinase; Diglycerides; Enzyme Inhibitors; Fluorescein Angiography; Hyperglycemia; Indoles; Isoenzymes; Male; Maleimides; Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Retina; Retinal Vessels | 1997 |
Involvement of adrenergic mechanism in hyperglycemia due to SCN stimulation.
Topics: Adrenergic alpha-Antagonists; Animals; Autonomic Nervous System; Electric Stimulation; Female; Glucagon; Hexamethonium; Hexamethonium Compounds; Hyperglycemia; Insulin; Propranolol; Quinazolines; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Suprachiasmatic Nucleus; Yohimbine | 1989 |